Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 23.5% in the fourth quarter, HoldingsChannel reports. The fund owned 67,068 shares of the company’s stock after acquiring an additional 12,776 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Kymera Therapeutics were worth $2,698,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of KYMR. Blue Trust Inc. raised its position in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. KBC Group NV raised its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares during the period. Quarry LP acquired a new position in shares of Kymera Therapeutics in the third quarter worth about $95,000. Thrivent Financial for Lutherans acquired a new position in shares of Kymera Therapeutics in the third quarter worth about $313,000. Finally, Arizona State Retirement System raised its position in shares of Kymera Therapeutics by 15.5% in the fourth quarter. Arizona State Retirement System now owns 11,221 shares of the company’s stock worth $451,000 after acquiring an additional 1,503 shares during the period.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares in the company, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,788 shares of company stock worth $455,202. 15.82% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Stock Up 2.6 %

Kymera Therapeutics stock opened at $32.54 on Friday. The firm has a market cap of $2.11 billion, a PE ratio of -13.91 and a beta of 2.22. Kymera Therapeutics, Inc. has a 52-week low of $29.07 and a 52-week high of $53.27. The company’s 50 day moving average is $38.23 and its two-hundred day moving average is $43.40.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. On average, equities research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

KYMR has been the subject of several research analyst reports. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price target for the company. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $38.00 to $57.00 in a report on Monday, December 2nd. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Finally, BTIG Research began coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.69.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.